Business Wire

euNetworks Adds a New High-Density Fibre Network in Brussels

Share

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the addition of a new duct and fibre-based network in Brussels to its Pan-European network footprint. This new addition takes the company’s owned and operated metropolitan network count to 18 in Europe. This is the latest of the company’s investments in digital infrastructure in the Benelux region, following the addition of a duct-based fibre network in Belgium through acquisition in April 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422857344/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

euNetworks' Metropolitan Network in Brussels, Belgium. (Graphic: Business Wire)

Last year, the 1,660 kilometres of fibre network acquired added unique routes in Brussels and long haul routes across Belgium, delivering a solid complement to euNetworks’ in-place network in the region. It also presented compelling additional investment opportunities for euNetworks in the long haul, in adjacent geographies and in building a new Brussels city network to give customers a truly end-to-end experience.

Since then, euNetworks has invested further in the Brussels metropolitan area, overbuilding acquired duct, purchasing additional cable and duct, and building additional high fibre count connectivity and diversity between key data centre sites, clusters and network aggregation points to deliver this new Brussels footprint.

Brussels Metro:

  • 41 kilometres of duct and high-fibre count network
  • Connects 5 data centres day 1, including LCL Brussels-North, Digital Realty BRU1, BRU3 & BRU4, AtlasEdge Brussels BRU001
  • With multiple, diverse entry points to these on-net data centres
  • Additional data centres are in the pipeline to be connected to support customer demand
  • Dark Fibre, Long Haul and Metro Wavelengths and Ethernet-based services are available across this footprint, with four diverse 100G Ethernet nodes to be installed, delivering resiliency and redundancy
  • Seamless connectivity between Brussels connected data centres and other regional data centre clusters and hubs in Ghent, Antwerp, Charleroi and Saint Ghislain
  • With multiple diverse long haul connectivity options from Brussels

“Belgium is a growing digital hub, with significant investment in the region to support emerging technology trends such as IoT and GenAI, which drive Cloud adoption and strategies,” said Paula Cogan, Chief Executive Officer of euNetworks. “Our Brussels and wider Belgium investments strengthen our leadership in European critical infrastructure as we focus on the ongoing densification of the high-bandwidth demand region of FLAP (Frankfurt, London, Amsterdam and Paris). We continue our approach to deliver a differentiated proposition to the market, offering unique and scalable network routes to our customers between key data centres. We also have a strong pipeline of ongoing investment to continue to support their growing bandwidth needs, further capitalising on the investment we made last year. I’m very proud of what the team have accomplished in a relatively short timeframe, delivering our eighteenth metro network to market. We’ve also expanded our local operations and sales presence, enabling strong support for our customers locally as they move forward with their infrastructure investments.”

euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 18 cities as well as a highly differentiated long haul network that spans 45,000 route kilometres across 17 countries. As a specialist in the sector, euNetworks continues to grow and invest in partnership with its customers, investing in new technologies and deepening its unique fibre network in Europe.

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 18 fibre-based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 536 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs.

The company delivers services with an active commitment to sustainability and is focused on its path to being carbon emissions net zero, environmentally responsible supply chain management and working as a community and industry to collaborate on the environmental challenges ahead. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hannah Britt| Chief Marketing Officer |euNetworks
5 Churchill Place | London E14 5HU
hannah.britt@eunetworks.com email | +44 7717 896 446 mobile

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye